NeuroPace

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroPace reports robust Q4 performance and outlines growth strategies

NeuroPace's Q4 call highlighted strong performance, strategic priorities for 2023, and challenges in maintaining gross margins. The company's focus on revenue growth drivers, market recovery, and new center expansions positions it well for future growth.

NeuroPace reports record revenue in Q1 2023, raises full-year guidance

NeuroPace delivered strong revenue growth in Q1 2023, with a positive outlook for the full year. The company faces challenges in managing operating expenses and sustaining profitability. However, opportunities lie in product distribution, clinical trials, and strategic growth initiatives.

NeuroPace excels in Q2, raises revenue guidance amid strategic growth

NeuroPace's Q2 performance reflects strong growth momentum and improved financial health, supported by strategic partnerships and effective expense management. The company's focus on expanding patient access and optimizing sales operations positions it well for continued success in 2023.

NeuroPace reports robust Q3 earnings, eyes strategic growth opportunities

NeuroPace's Q3 performance reflects strong revenue growth, improved margins, and prudent cost management, positioning the company for sustained success.
While facing challenges in net losses and operating expenses, NeuroPace's operational achievements and financial stability provide a solid foundation for future growth.
By addressing cost structures, leveraging market opportunities, and adapting to evolving market dynamics, NeuroPace can enhance profitability and drive long-term value creation.

NeuroPace reports robust revenue growth and strategic collaborations for 2024

NeuroPace's strong performance in Q4 2023 and full-year results demonstrate growth momentum.
Strategic collaborations and a focus on cost management are key strengths.
Challenges include managing expenses and market dynamics, but growth opportunities are present.
Overall, NeuroPace is well-positioned for revenue growth and transformative impact in 2024.

NeuroPace reports strong Q1 revenue growth and strategic collaborations

NeuroPace's Q1 2024 performance reflects revenue growth, margin improvements, and strategic collaborations.
The company faces challenges in maintaining margins, financial discipline, and closing the treatment gap.
Opportunities lie in expanding therapy access, market growth, and executing the growth strategy.
Overall, NeuroPace is on track to drive revenue through product sales and strategic initiatives.

NeuroPace reports robust Q2 earnings, eyes growth through strategic initiatives

NeuroPace's Q2 2024 performance reflects revenue growth, improved gross margin, and strategic initiatives driving future expansion and market penetration.
While facing challenges in managing operating expenses and maintaining margins, the company's strong cash position and growth strategy present opportunities for sustained growth.
Overall, NeuroPace's focus on innovation, market expansion, and financial prudence positions it well for future success in the neurotechnology sector.

NeuroPace reports robust Q3 earnings, eyes growth in epilepsy market

NeuroPace's Q3 2024 performance reflects solid revenue growth, operational improvements, and strategic focus on innovation and market expansion.
While facing challenges such as operating losses and competitive pressures, the company is well-positioned to leverage growth opportunities in the epilepsy treatment market.
With a strong financial position, effective leadership enhancements, and proactive investor engagement, NeuroPace is poised for continued growth and market success.
Strategic initiatives and upcoming events underscore the company's commitment to driving value for stakeholders and advancing its position in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors.

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors

MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )--NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility investigational device exemption (IDE) study. LGS is a devastating form of childhood onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury. The study uses the RNS® System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to test whether brain-responsive neurostimulation can also be used to treat LGS.

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

Fintel reports that Accelmed Partners II L.P.

Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results

Neuropace, Inc. (NASDAQ:NPCE ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Allen Gong - JPMorgan Chase & Co. Lawrence Biegelsen - Wells Fargo Securities Operator Good day, and thank you for standing by. Welcome to the Q3 2022 NeuroPace earnings conference call.

Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript

MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022.

NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update

MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe Research Healthcare Conference. Management is scheduled to present on Wednesday, November 16th at 2:40 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event.

NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference

MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a commercial stage medical device company focused on transforming the lives of people living with epilepsy, today announced the first patient implanted in the NAUTILUS clinical study. The pivotal study will evaluate the safety and effectiveness of the RNS® System in individuals aged 12 and older with drug-resistant idiopathic generalized epilepsy (IGE), also known as primary generalized epilepsy. The first procedure took pl

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

MOUNTAIN VIEW, Calif. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management is scheduled to present on Tuesday, September 13 at 12:20 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event

NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robert Marcus - JPMorgan Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2022 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending June 30, 2022.

NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update

Agreement will provide NeuroPace with exclusive rights to market and sell DIXI Medical's diagnostic electrodes for epilepsy in the U.S. Agreement will provide NeuroPace with exclusive rights to market and sell DIXI Medical's diagnostic electrodes for epilepsy in the U.S.

NeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for Neurosurgery

MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 11, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022

NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Bacso – Investor Relations Mike Favet – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Larry Biegelsen – Wells Fargo Michael Polark – Wolfe Research Danielle Antalffy – SVB Securities Drew Ranieri – Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q1 2022 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets Global Healthcare Conference. Mike Favet, CEO, is scheduled to present on Tuesday, May 17 at 9:30 a.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event.

NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending March 31, 2022.

NeuroPace Reports First Quarter 2022 Financial Results

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced that the first patient was treated in the RESPONSE clinical trial, which will evaluate the safety and effectiveness of the RNS® System in adolescent patients with drug-resistant focal epilepsy. The procedure took place at Westchester Medical Center in New York and follow-up appointments will be conducted at Boston Children's

NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents

MOUNTAIN VIEW, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 12, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace to Report First Quarter 2022 Financial Results on May 12, 2022

EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device

Bear of the Day: NeuroPace (NPCE)

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 10, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) --  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am Eastern Time.

News for NeuroPace Stock (NPCE)